Prescription. GMS. Sport Permitted.
Boehringer Ingelheim and Pfizer Healthcare are pleased to announce the introduction of Spiriva Respimat this month. The Respimat Soft Mist Inhaler is a new delivery device for Spiriva (tiotropium bromide).
The Respimat Soft Mist Inhaler represents a new generation in inhaler design. It is a propellant free device, which uses the energy generated from a spring. It delivers a slow moving, long lasting aerosol cloud, with high lung deposition. In clinical studies of inhaler devices, more patients preferred Respimat Soft Mist inhaler to other delivery devices tested; 81% of patients preferred the Respimat Soft Mist Inhaler compared to a standard MDI. Spiriva Respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with COPD. The recommended dose of Spiriva Respimat is 5μg once daily, given as two consecutive puffs from the Respimat inhaler. In clinical trials, this dose has been shown to produce comparable therapeutic effects to Spiriva 18μg given by the HandiHaler (see New Clinical Evidence section). Should you need any further details please do not hesitate to contact Boehringer Ingelheim Ireland Ltd at (01) 2959620.